

168/IFW ★




## UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/509,917	FIRST NAMED APPLICANT Peter Muhlradt	ATTY. DOCKET NO. 03100215AA
-------------------------------------------	-----------------------------------------	--------------------------------

30743  
 WHITHAM, CURTIS & CHRISTOFFERSON, P.C.  
 11491 SUNSET HILLS ROAD  
 SUITE 340  
 RESTON, VA 20190



INTERNATIONAL APPLICATION NO. PCT/EP03/03497	
I.A. FILING DATE 04/03/2003	PRIORITY DATE 04/04/2002



CONFIRMATION NO. 4470

371 FORMALITIES LETTER



\*OC000000016108802\*

Date Mailed: 05/25/2005

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.

- Send e-mail correspondence for Patent Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

DONNA S GREENE

Telephone: (703) 308-9140 EXT 222

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/509,917	PCT/EP03/03497	03100215AA

FORM PCT/DO/EO/922 (371 Formalities Notice)

JUN 28 2005

**TRANSMITTAL LETTER**  
**(General - Patent Pending)**

Docket No.  
**03100215AA**

In Re Application Of: **P. Muhlradt, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/509,917	October 4, 2004	Unassigned	30743	1645	4470

Title: **USE OF A LIPOPEPTIDE OR LIPOPROTEIN AS AN ADJUVANT IN THERAPEUTIC OR PROPHYLACTIC VACCINATIONS**

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

**STATEMENT TO SUPPORT FILING AND SUBMISSION ; SUBMISSION OF SEQUENCE LISTING AND STATEMENT TO SUPPORT FILING; COPY OF NOTICE TO COMPLY WITH SEQUENCE DISCLOSURE; SEQUENCE DISK/PAPER**

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **50-2041** as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

  
Signature

Dated: **June 28, 2005**

Ruth Tyler-Cross  
Reg no. 45,922  
Whitham, Curtis & Christofferson, PC  
11491 Sunset Hills Road, Suite 340  
Reston, Virginia 20190  
703-787-9400

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature of Person Mailing Correspondence

**HAND DELIVERED**

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Correspondence

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

*In re* patent application of Guzman et al.

Serial number: 10/509,917

Group Art Unit: 1645

Attorney Docket Number: 03100215aa

Examiner: Unassigned

International Filing Date: April 3, 2003

**For: "USE OF A LIPOPEPTIDE OR LIPOPROTEIN AS ADJUVANT IN THERAPEUTIC  
OR PROPHYLACTIC VACCINATION"**

SUBMISSION OF SEQUENCE LISTING AND STATEMENT TO SUPPORT FILING IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents

PO Box 1450

Alexandria VA 22313-1450

**Mail Stop SEQUENCE**

Dear Sir:

In response to a Notice To Comply with Requirements for Patent Applications, mailed 05/05/2005, we enclose herein an initial computer readable form (diskette) and a paper copy of the sequence listings for the above-identified patent application. Also enclosed is a verified statement that the content of the paper and computer readable copies are the same and include no new matter. Applicant respectfully requests amendment of the present application by entry of the Sequence Listing.

Respectfully submitted,

Ruth E. Tyler-Cross

Registration No. 45,922

Whitham, Curtis & Christofferson  
11491 Sunset Hills Road; Suite 340  
Reston, AA 20190  
Tel: 703-787-9400  
FAX: 703-787-7557